Title of Invention	PROCESS FOR THE PURIFICATION OF CITALOPRAM
Abstract	The present invention relates to an industrially advantageous method for the purification of Citalopram wherein desmethyl citalopram (Formula II), present in crude Citalopram as an impurity, is methylated to produce pure Citalopram of Formula I. The resulting Citalopram product is isolated as the base or a pharmaceutically acceptable salt thereof

Full Text

FIELD OF THE INVENTION The present invention relates to an industrially advantageous process for the purification of Citalopram having desmethyl citalopram as an impurity, to prepare pure Citalopram of Formula I. The resulting Citalopram product is isolated as the base or a pharmaceutical ly acceptable salt thereof. BACKGROUND OF THE INVENTION Citalopram of Formula I is a well known antidepressant drug that has now been on the market for several years and is chemically known as l-[3-(dimethylamino)propyl]-l-(4-fluorophenyl)-l,3-dihydroisobenzofuran-5-carbonitrile. Citalopram is a selective centrally acting serotonin reuptake inhibitor and it has further been shown to be effective in the treatment of dementia and cerebrovascular disorder as described in European Patent 0 474 580. Citalopram was first disclosed in US Patent 4,136,193. This patent publication outlines a process for preparation of Citalopram from corresponding 5-bromo derivative by reaction with cuprous cyanide. Further, variants of this method are disclosed in PCT Applications, WO 00/13648 and WO 00/11926 wherein the exchange of 5-halogen or 5-CF3-(CF2)n-SO2-0- with cyano is achieved with cyanide source in the presence of palladium or nickel catalyst. The processes comprising exchange of 5-halogen with cyano as described above have been found to give high molecular weight fmpurities and desmethyl citalopram in unacceptable quantities. PCT Application WO 01/47877 describes a process of film distillation to remove high molecular weight impurities formed during cyanide exchange reaction. However, desmethyl citalopram distils alongwith Citalopram and it is not easy to remove this impurity by usual purification procedures. PCT Application WO 01/45483 teaches an acylation method that effectively removes desmethyl citalopram. This comprises treating the crude product with an acylating agent such as an acid anhydride or an acid halide wherein desmethyl citalopram forms an amide derivative and is removed by acid / base wash followed by crystallization to obtain pure Citalopram, While desmethyl citalopram gets removed in this process as an amide derivative, yield loss coupled with purification involving a chemical step makes this process untenable to operate on industrial scale. US patent 6,420,574 teaches a method for the preparation of citalopram from the compound of the following formula wherein R represents -CHs-OPg, CH2-NPg,Pg2, CHjNMePg, CO-N-(CH3)2, CH2-CO-NH2, Pg represents protection groups for an amino group by converting R group to a dimethylaminomethyl group. In one of exemplified process desmethyl citalopram oxalate salt has been converted to citalopram by methylation using formaldehyde and formic acid at reflux temperature for 4 hrs, followed by acid base treatment, and subsequently isolation of citalopram oxalate from acetone. But the process is time consuming and results in low yields. Moreover, the purity of the compound is also not reported. However, the process described in this patent aims at preparing citatopram oxalate from desmethyl citalopram oxalate and not purification of citalopram. Therefore, it is an object of the present invention to provide a simple and commercially attractive process for removing desmethyl impurity from crude citalopram. It has been found that crude Citalopram containing desmethyl impurity can be methylated to produce highly pure Citalopram in high yield. SUMMARY OF THE INVENTION The present invention relates to a process for the purification of Citalopram having desmethyl citalopram of Formula II as an impurity characterized in that //-methylation of Formula II is carried out by treating the crude Citalopram in the presence of formic acid with 35% aqueous solution of formaldehyde at a temperature of 85-95°C for 30 min to obtain highly pure Citalopram, preparing citalopram oxalate by treatment with oxalic acid in ethanol at a temperature of 20-25'^C and converting citalopram oxalate to the pharmaceutically acceptable salt. DETAILED DESCRIPTION OF THE INVENTION The instant invention relates to a novel process whereby the desmethyl citalopram impurity (Formula II), present in crude Citalopram, is transformed to Citalopram by methylation to produce pure Citalopram (Formula I). Specifically, the present invention involves reacting crude Citalopram with formaldehyde and formic acid to accomplish the methylation of desmethyl impurity to obtain pure Citalopram. This purification method of Citalopram is simple and efficient and provides quantitative conversion of desmethyl citalopram into Citalopram thereby resulting in increased Citalopram yield. The crude Citalopram may be prepared by the cyanide exchange reaction of corresponding 5-bromo derivative as described in US 4,136,193. The methylation is carried out by treating the crude Citalopram with formaldehyde and formic acid. Formaldehyde employed in the methylation reaction is 35% aqueous solution and is used in an amount up to 3 moles per mole of desmethyl content present in crude Citalopram. Formic acid is used up to 6 moles per mole of desmethyl content. The said reaction is conducted in neat without adding any solvent. Typically, the methylation is completed by heating crude Citalopram with formaldehyde and formic acid at a temperature of 85-95°C for 30 min. After methylation, the reaction mass as such is diluted with ethanol and oxalic acid is added to isolate Citalopram oxalate which is free from desmethyl impurity. The oxalate salt can further be crystallized from ethanol to consistently attain more than 99.5% purity. The major advantage realized in the present purification process as compared to prior art of removing desmethyl impurity is the increased process productivity as impurity is converted to the Citalopram. Moreover, no additional chemical / isolation step is needed to remove desmethyl impurity. Also, this procedure demonstrates a greater efficiency than the prior art. The Citalopram oxalate thus obtained can be converted to pharmaceutically acceptable highly pure Citalopram hydrobromide salt by the conditions well known in the art. Further, details of the present invention are to be found in the following example without limiting it: Example A) PREPARA T/ON OF CRUDE CITALOPRAM BASE: Cuprous cyanide (85.4 g, 0.95 mol) was added to 5-bromo-l-(3-dimethyl aminopropyl)-l-(4-fluorophenyl)-l,3-dihydroisobenzofuran (200 g, 0.53 mol) and contents were heated to 140-150°C. After completion of reaction, N,N-dimethylformamide (200 ml) was added and reaction mass was ftirther diluted with toluene (500 ml). The reaction mixture was cooled to SO^'C where aqueous ethylenediamine (50% w/v) was added and layers were separated. The organic layer was washed sequentially with aqueous EDTA (2% w/v) and water (2x200 ml). The organic layer was concentrated under reduced pressure to remove toluene. The residue was distilled in vacuum and crude Citalopram was obtained as oil. Yield: 110 g. The product contained 7% of desmethyl citalopram by HPLC. B) PURIFICA TION OF CRUDE CITALOPRAM: To the crude Citalopram (90 g, 0.28 mol) obtained in accordance with Step-A having desmethyl citalopram (7%, HPLC), formic acid (98%, 2.7 g) was added followed by aqueous formaldehyde (35%), 2.37 g). The reaction mass was heated at 85-95°C for 30 min. HPLC indicated complete conversion of desmethyl impurity into Citalopram. The reaction mass was cooled to 30°C and diluted with ethanol (900 ml). Oxalic acid dihydrate (41.94 g, 0.33 mol) was added and mass was heated to reflux. The obtained solution was cooled to 20-25°C and stirring was continued for 2 hours at 20-25°C. The product thus obtained was filtered and crystallized from ethanol to provide highly pure 92 g of crystalline Citalopram oxalate having HPLC purity 99.7% and desmethyl citalopram impurity: not detected. C) PREPARA TION OF CITALOPRAM HYDROBROMIDE: DM water (880 ml) was added to Citalopram oxalate as obtained above (88 g) followed by addition of toluene (700 ml). The pH of the mixture was adjusted to 9.2-9.6 with aqueous ammonia. The organic layer was separated, washed with DM water and thereafter toluene was removed under reduced pressure. Acetone (620 ml) was added to the residue followed by the addition of 48% aqueous hydrobromic acid solution (25 g). The solvent was distilled out under reduced pressure at 30-55°C. Fresh acetone (240 ml) was added and refluxed for 30 min. The reaction mixture was cooled to 5-10°C and stirred for 5 hours. The crystalline product thus obtained was filtered, washed sequentially with chilled cyclohexane and acetone and dried to obtain Citalopram hydrobromide (79.2 g) having HPLC purity 99.8%. WE CLAIM (1) A process for the purification of Citalopram having desmethyl citalopram of Formula II as an impurity characterized in that N-methylation of Formula II is carried out by treating the crude Citalopram in the presence of formic acid with 35% aqueous solution of formaldehyde at a temperature of 85-95oC for 30 min to obtain highly pure Citalopram, preparing citalopram oxalate by treatment with oxalic acid in ethanol at a temperature of 20-25°C and converting citalopram oxalate to the pharmaceutically acceptable salt. (2) The process of purification of Citalopram according to claim-1 wherein the isolation step is not required to remove desmethyl impurity. (3) The process of purification of Citalopram according to claim-1 wherein the purified Citalopram is having purity greater than 99,5%.

Documents:

225-che-2003-abstract.pdf

225-che-2003-claims duplicate.pdf

225-che-2003-claims original.pdf

225-che-2003-correspondnece-others.pdf

225-che-2003-correspondnece-po.pdf

225-che-2003-description(complete) duplicate.pdf

225-che-2003-description(complete) original.pdf

225-che-2003-form 1.pdf

225-che-2003-form 19.pdf

225-che-2003-form 26.pdf

225-che-2003-form 3.pdf

225-che-2003-pct.pdf